Adalimumab Market Research and Clinical Analysis 2019 to 2025: Janssen Biotech, GlaxoSmithKline, Sanofi, MedImmune, UCB, Novartis
The global Adalimumab market is expected to increase during the forecast period. Adalimumab is a monoclonal antibody used for the treatment of immune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, chronic psoriasis, ulcerative colitis, and juvenile idiopathic arthritis.
Dublin, India – February 25, 2019 /MarketersMedia/ —
The global Adalimumab market is expected to increase during the forecast period. Adalimumab is a monoclonal antibody used for the treatment of immune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, chronic psoriasis, ulcerative colitis, and juvenile idiopathic arthritis.
Inquire for Discount Upto 50% on Adalimumab market 2019-25 Report at: https://inforgrowth.com/requestdiscount/r/1002787/prof-researchglobal-adalimumab-market-report-2019-history-present-and-future
The rising prevalence of rheumatoid arthritis is the most important factor driving the Adalimumab market. Additionally, the increasing number of indications for which the drug can be used as a treatment option is driving the growth of this market. AbbVie holds the patent for the drug marketed under the name Humira. The company is continuously investing in lifecycle management of the drug. In the year 2016, the company introduced the Humira Pen, which is a self-injecting device. The device is in Phase III clinical trials for 3 additional indications.
However, the patent expiry of the drug in Europe in 2018, will lead to the entry of new biosimilars in the European market. The NHS spends approximately 500 million euros on Humira. The launch of new biosimilars will help decrease this spending. The United States is a major market for Humira, where it has patent exclusivity up to early 2023.
Key Players covered in this report are Janssen Biotech, GlaxoSmithKline, Sanofi, MedImmune, UCB, Novartis.
The Adalimumab market report covers major regions like North America, South America, Asia & Pacific, Europe and MEA (Middle East and Africa).
For competitor segment, the report includes global key players of Adalimumab as well as some small players. The information for each competitor includes:
Company Profile
Main Business Information
SWOT Analysis
Sales, Revenue, Price and Gross Margin
Market Share
Major Points from Table of Contents
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Current Adalimumab in North America (2013-2018)
Chapter 10 Historical and Current Adalimumab in South America (2013-2018)
Chapter 11 Historical and Current Adalimumab in Asia & Pacific (2013-2018)
Chapter 12 Historical and Current Adalimumab in Europe (2013-2018)
Chapter 13 Historical and Current Adalimumab in MEA (2013-2018)
Chapter 14 Summary for Global Adalimumab (2013-2018)
Chapter 15 Global Adalimumab Forecast (2019-2023)
Chapter 16 Analysis of Global Key Vendors
Connect With Our Expert Research Team To Build Custom Research On This Topic By Clicking Here https://inforgrowth.com/customizationrequest/r/1002787/prof-researchglobal-adalimumab-market-report-2019-history-present-and-future
Contact Info:
Name: Rohan
Email: Send Email
Organization: InForGrowth
Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA
Phone: +1-909-329-2808
Website: http://www.inforgrowth.com
Source: MarketersMedia
Release ID: 485717
Copyright © 1999-2013 SproutNews.com
